Recently, the Dorzagliatin Tablet (Chinese trade name: 华堂宁) as a NME (new molecule entity) is approved for marketing by China NMPA. Dorzagliatin, developed by HUA Medicine Shanghai, is approved for improving the blood glucose control for adult patients with type 2 diabetes.

　　Dozaglietine is a glucokinase (GK) activator, which can act on GK target in organs of pancreas, intestine and liver to regulate glucose storage and output, so as to restore the blood glucose homeostasis in patients with type 2 diabetes. This drug provides a new treatment option available for patients with type 2 diabetes.